Skip to main content
Erschienen in: Diabetologia 4/2006

01.04.2006 | Article

Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs

verfasst von: L. Simonsen, J. J. Holst, C. F. Deacon

Erschienen in: Diabetologia | Ausgabe 4/2006

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The insulinotropic hormone, glucagon-like peptide-1 (GLP-1), is rapidly degraded in vivo as a result of the combination of extensive enzymatic degradation and renal extraction. The GLP-1 receptor agonist, exendin-4, has a longer duration of action, and has recently been approved as a new agent for the treatment of type 2 diabetes mellitus. Exendin-4 is less prone to enzymatic degradation, but it is still unclear what other factors contribute to the increased metabolic stability.

Materials and methods

The overall metabolism of GLP-1 and exendin-4 was directly compared in anaesthetised pigs (n=9).

Results

Metabolism of GLP-1 (C-terminal RIA; t 1/2 2.0±0.2 min, metabolic clearance rate [MCR] 23.2±2.8 ml min−1 kg−1; N-terminal RIA; t 1/2 1.5±0.2 min, MCR 88.1±10.6 ml min−1 kg−1) was significantly faster than the metabolism of exendin-4 (t 1/2 22.0±2.1 min, p<0.0001; MCR 1.7±0.3 ml min−1 kg−1, p<0.01). Differences in arteriovenous concentrations revealed organ extraction of GLP-1 by the kidneys (C-terminal 56.6±2.6%; N-terminal 48.3±5.9%), liver (N-terminal 41.4±3.8%), and peripheral tissues (C-terminal 42.3±6.0%; N-terminal 33.0±7.8%), whereas organ extraction of exendin-4 was limited to the kidneys (21.3±4.9%). While the renal extraction of exendin-4 (6.9±2.5 pmol/min) did not differ significantly from the amount undergoing glomerular filtration (8.4±2.0 pmol/min), the renal extraction of C-terminal GLP-1 (9.0±1.1 pmol/min), exceeded the amount which could be accounted for by glomerular filtration (4.2±0.5 pmol/min, p<0.0005).

Conclusions/interpretation

In addition to an increased resistance to enzymatic degradation, the increased stability of exendin-4 is the result of reduced differential organ extraction compared to GLP-1. The data suggest that in the anaesthetised pig, extraction occurs only in the kidney and can be fully accounted for by glomerular filtration.
Literatur
1.
Zurück zum Zitat Deacon CF, Ahren B, Holst JJ (2004) Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opin Investig Drugs 13:1091–1102CrossRefPubMed Deacon CF, Ahren B, Holst JJ (2004) Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opin Investig Drugs 13:1091–1102CrossRefPubMed
2.
Zurück zum Zitat Vilsboll T, Agerso H, Krarup T, Holst JJ (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220–224CrossRefPubMed Vilsboll T, Agerso H, Krarup T, Holst JJ (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220–224CrossRefPubMed
3.
Zurück zum Zitat Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741–744CrossRefPubMed Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741–744CrossRefPubMed
4.
Zurück zum Zitat Zander M, Madsbad S, Madsen JL, Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824–830CrossRefPubMed Zander M, Madsbad S, Madsen JL, Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824–830CrossRefPubMed
5.
Zurück zum Zitat Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829–835CrossRefPubMed Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829–835CrossRefPubMed
6.
Zurück zum Zitat Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ (1996) Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 271:E458–E464PubMed Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ (1996) Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 271:E458–E464PubMed
7.
Zurück zum Zitat Gallwitz B, Schmidt WE, Conlon JM, Creutzfeldt W (1990) Glucagon-like peptide-1(7–36)amide: characterization of the domain responsible for binding to its receptor on rat insulinoma RINm5F cells. J Mol. Endocrinol 5:33–39PubMed Gallwitz B, Schmidt WE, Conlon JM, Creutzfeldt W (1990) Glucagon-like peptide-1(7–36)amide: characterization of the domain responsible for binding to its receptor on rat insulinoma RINm5F cells. J Mol. Endocrinol 5:33–39PubMed
8.
Zurück zum Zitat Hupe-Sodmann K, McGregor GP, Bridenbaugh R et al (1995) Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 58:149–156CrossRefPubMed Hupe-Sodmann K, McGregor GP, Bridenbaugh R et al (1995) Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 58:149–156CrossRefPubMed
9.
Zurück zum Zitat Plamboeck A, Holst JJ, Carr RD, Deacon CF (2005) Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 48:1882–1890CrossRefPubMed Plamboeck A, Holst JJ, Carr RD, Deacon CF (2005) Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 48:1882–1890CrossRefPubMed
10.
Zurück zum Zitat Hassan M, Eskilsson A, Nilsson C et al (1999) In vivo dynamic distribution of 131I-glucagon-like peptide-1 (7–36) amide in the rat studied by gamma camera. Nucl Med Biol 26:413–420CrossRefPubMed Hassan M, Eskilsson A, Nilsson C et al (1999) In vivo dynamic distribution of 131I-glucagon-like peptide-1 (7–36) amide in the rat studied by gamma camera. Nucl Med Biol 26:413–420CrossRefPubMed
11.
Zurück zum Zitat Meier JJ, Nauck MA, Kranz D et al (2004) Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53:654–662PubMedCrossRef Meier JJ, Nauck MA, Kranz D et al (2004) Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53:654–662PubMedCrossRef
12.
Zurück zum Zitat Ruiz-Grande C, Alarcon C, Alcantara A et al (1993) Renal catabolism of truncated glucagon-like peptide 1. Horm Metab Res 25:612–616PubMed Ruiz-Grande C, Alarcon C, Alcantara A et al (1993) Renal catabolism of truncated glucagon-like peptide 1. Horm Metab Res 25:612–616PubMed
13.
Zurück zum Zitat Eng J, Kleinman WA, Singh L, Singh G, Raufman JP (1992) Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267:7402–7405PubMed Eng J, Kleinman WA, Singh L, Singh G, Raufman JP (1992) Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267:7402–7405PubMed
14.
Zurück zum Zitat Edwards CM, Stanley SA, Davis R et al (2001) Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281:E155–E161PubMed Edwards CM, Stanley SA, Davis R et al (2001) Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281:E155–E161PubMed
15.
Zurück zum Zitat Thum A, Hupe-Sodmann K, Goke R, Voigt K, Goke B, McGregor GP (2002) Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4. Exp Clin Endocrinol Diabetes 110:113–118PubMedCrossRef Thum A, Hupe-Sodmann K, Goke R, Voigt K, Goke B, McGregor GP (2002) Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4. Exp Clin Endocrinol Diabetes 110:113–118PubMedCrossRef
16.
Zurück zum Zitat Deacon CF, Danielsen P, Klarskov L, Olesen M, Holst JJ (2001) Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 50:1588–1597PubMedCrossRef Deacon CF, Danielsen P, Klarskov L, Olesen M, Holst JJ (2001) Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 50:1588–1597PubMedCrossRef
17.
Zurück zum Zitat Trebbien R, Klarskov L, Olesen M, Holst JJ, Carr RD, Deacon CF (2004) Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs. Am J Physiol Endocrinol Metab 287:E431–E438CrossRefPubMed Trebbien R, Klarskov L, Olesen M, Holst JJ, Carr RD, Deacon CF (2004) Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs. Am J Physiol Endocrinol Metab 287:E431–E438CrossRefPubMed
18.
Zurück zum Zitat Hvidberg A, Nielsen MT, Hilsted J, Orskov C, Holst JJ (1994) Effect of glucagon-like peptide-1 (proglucagon 78–107amide) on hepatic glucose production in healthy man. Metabolism 43:104–108PubMedCrossRef Hvidberg A, Nielsen MT, Hilsted J, Orskov C, Holst JJ (1994) Effect of glucagon-like peptide-1 (proglucagon 78–107amide) on hepatic glucose production in healthy man. Metabolism 43:104–108PubMedCrossRef
19.
Zurück zum Zitat Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535–539PubMedCrossRef Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535–539PubMedCrossRef
20.
Zurück zum Zitat Orskov C, Jeppesen J, Madsbad S, Holst JJ (1991) Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87:415–423PubMedCrossRef Orskov C, Jeppesen J, Madsbad S, Holst JJ (1991) Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87:415–423PubMedCrossRef
21.
Zurück zum Zitat Kreymann B, Williams G, Ghatei MA, Bloom SR (1987) Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet 2:1300–1304CrossRefPubMed Kreymann B, Williams G, Ghatei MA, Bloom SR (1987) Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet 2:1300–1304CrossRefPubMed
22.
Zurück zum Zitat Booth AG, Kenny AJ (1976) Proteins of the kidney microvillus membrane. Identification of subunits after sodium dodecylsulphate/polyacrylamide-gel electrophoresis. Biochem J 159:395–407PubMed Booth AG, Kenny AJ (1976) Proteins of the kidney microvillus membrane. Identification of subunits after sodium dodecylsulphate/polyacrylamide-gel electrophoresis. Biochem J 159:395–407PubMed
23.
Zurück zum Zitat Lambeir AM, Proost P, Scharpe S, De MI (2002) A kinetic study of glucagon-like peptide-1 and glucagon-like peptide-2 truncation by dipeptidyl peptidase IV, in vitro. Biochem Pharmacol 64:1753–1756CrossRefPubMed Lambeir AM, Proost P, Scharpe S, De MI (2002) A kinetic study of glucagon-like peptide-1 and glucagon-like peptide-2 truncation by dipeptidyl peptidase IV, in vitro. Biochem Pharmacol 64:1753–1756CrossRefPubMed
24.
Zurück zum Zitat Hartmann B, Harr MB, Jeppesen PB et al (2000) In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 85:2884–2888CrossRefPubMed Hartmann B, Harr MB, Jeppesen PB et al (2000) In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 85:2884–2888CrossRefPubMed
25.
Zurück zum Zitat Neidigh JW, Fesinmeyer RM, Prickett KS, Andersen NH (2001) Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states. Biochemistry 40:13188–13200CrossRefPubMed Neidigh JW, Fesinmeyer RM, Prickett KS, Andersen NH (2001) Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states. Biochemistry 40:13188–13200CrossRefPubMed
26.
Zurück zum Zitat Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A (1993) Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45:87–146PubMed Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A (1993) Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45:87–146PubMed
27.
Zurück zum Zitat Parkes D, Jodka C, Smith P et al (2001) Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon like peptide-1. Drug Development and Research 53:260–267CrossRef Parkes D, Jodka C, Smith P et al (2001) Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon like peptide-1. Drug Development and Research 53:260–267CrossRef
28.
Zurück zum Zitat Mentlein R (1999) Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides. Regul Pept 85:9–24CrossRefPubMed Mentlein R (1999) Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides. Regul Pept 85:9–24CrossRefPubMed
29.
Zurück zum Zitat Moreno C, Mistry M, Roman RJ (2002) Renal effects of glucagon-like peptide in rats. Eur J Pharmacol 434:163–167CrossRefPubMed Moreno C, Mistry M, Roman RJ (2002) Renal effects of glucagon-like peptide in rats. Eur J Pharmacol 434:163–167CrossRefPubMed
30.
Zurück zum Zitat Yamamoto H, Lee CE, Marcus JN et al (2002) Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110:43–52CrossRefPubMed Yamamoto H, Lee CE, Marcus JN et al (2002) Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110:43–52CrossRefPubMed
31.
Zurück zum Zitat Peterson DR, Green EA, Oparil S, Hjelle JT (1986) Transport and hydrolysis of glucagon in the proximal nephron. Am J Physiol 251:F460–F467PubMed Peterson DR, Green EA, Oparil S, Hjelle JT (1986) Transport and hydrolysis of glucagon in the proximal nephron. Am J Physiol 251:F460–F467PubMed
32.
Zurück zum Zitat Carone FA, Peterson DR, Flouret G (1982) Renal tubular processing of small peptide hormones. J Lab Clin Med 100:1–14PubMed Carone FA, Peterson DR, Flouret G (1982) Renal tubular processing of small peptide hormones. J Lab Clin Med 100:1–14PubMed
33.
Zurück zum Zitat Emmanouel DS, Jaspan JB, Rubenstein AH, Huen AH, Fink E, Katz AI (1978) Glucagon metabolism in the rat. J Clin Invest 62:6–13PubMed Emmanouel DS, Jaspan JB, Rubenstein AH, Huen AH, Fink E, Katz AI (1978) Glucagon metabolism in the rat. J Clin Invest 62:6–13PubMed
34.
Zurück zum Zitat Linnebjerg H, Kothare P, Park S et al (2005) Exenatide pharmacokinetics in patients with mild to moderate renal dysfunction and end stage renal disease. ADA 2005. (Abstract) Linnebjerg H, Kothare P, Park S et al (2005) Exenatide pharmacokinetics in patients with mild to moderate renal dysfunction and end stage renal disease. ADA 2005. (Abstract)
Metadaten
Titel
Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs
verfasst von
L. Simonsen
J. J. Holst
C. F. Deacon
Publikationsdatum
01.04.2006
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 4/2006
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-0128-9

Weitere Artikel der Ausgabe 4/2006

Diabetologia 4/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.